GSK and Concert sign $1 billion deal for deuterium-modified drugs
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to pay the private US company Concert Pharmaceuticals $35 million up-front as well as future milestones and royalties to develop and commercialise three of its deuterium-containing programmes.